Astex Pharmaceuticals Inc Pleasanton CA; and

Centre Hospitalier Lyon Sud Pierre Bénite France

China Medical University Hospital Taichung Taiwan Republic of China

Copernicus Memorial Hospital Lodz Poland; Department of Hematology Medical University of Lodz Lodz Poland

Coriell Institute for Medical Research Camden NJ

Division of Hematology and Medical Oncology Weill Cornell Medicine Cornell University New York NY

Fakultní Nemocnice Brno Czech Republic

Fakultní Nemocnice Královské Vinohrady Praha Czech Republic

Groupe Hospitalier de la Région Mulhouse Sud Alsace Mulhouse France

Hôpital Saint Louis Paris France

Leukemia Service Department of Medicine Memorial Sloan Kettering Cancer Center New York NY

MD Anderson Cancer Center University of Texas Houston TX

Multiprofile Hospital for Active Treatment Sveta Marina EAD Varna Bulgaria

Nagasaki University Hospital Nagasaki Japan

NewYork Presbyterian Hospital New York NY

Ospedale Policlinico San Martino Genova Italy

Princess Margaret Cancer Centre Toronto Canada

Roswell Park Cancer Institute Buffalo NY

Section of Hematology Department of Medicine Yale University New Haven CT

Semmelweis Egyetem Budapest Hungary

Severance Hospital Yonsei University Health System Seoul Republic of Korea

Städtisches Klinikum Braunschweig Braunschweig Germany

Ulm University Hospital Ulm Germany

University of Alberta Hospital Edmonton Canada

Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Warsaw Poland

Yale Cancer Center New Haven CT

See more in PubMed

DiNardo CD, Jonas BA, Pullarkat V, et al. . Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629. PubMed

Wei AH, Montesinos P, Ivanov V, et al. . Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137-2145. PubMed PMC

Dombret H, Seymour JF, Butrym A, et al. . International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291-299. PubMed PMC

Kantarjian HM, Thomas XG, Dmoszynska A, et al. . Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670-2677. PubMed PMC

Zeidan AM, Wang R, Wang X, et al. . Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192-2201. PubMed PMC

Fenaux P, Gobbi M, Kropf P, et al. Results of ASTRAL-1 study, a phase 3 randomized trial of guadecitabine (G) vs treatment choice (TC) in treatment naïve acute myeloid leukemia (TN-AML) not eligible for intensive chemotherapy (IC). Presented at the 24th Congress of the European Hematology Association. 13-16 June 2019. Amsterdam, The Netherlands.

Zeidan AM, Fenaux P, Gobbi M, et al. Comparative results of azacitidine and decitabine from a large prospective phase 3 study in treatment naive patients with acute myeloid leukemia not eligible for intensive chemotherapy. Presented at the 62nd American Society of Hematology Annual Meeting. 5-8 December 2020.

Cheson BD, Bennett JM, Kopecky KJ, et al. ; International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia [published correction appears in J Clin Oncol. 2004;22(3):576]. J Clin Oncol. 2003;21(24):4642-4649. PubMed

DiNardo CD, Pratz K, Pullarkat V, et al. . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17. PubMed PMC

Brunner AM, Esteve J, Porkka K, et al. . Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study [abstract]. Blood. 2021;138(suppl 1): 244.

Short NJ, Kantarjian HM, Loghavi S, et al. . Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. Lancet Haematol. 2019;6(1):e29-e37. PubMed PMC

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study